Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-10-04 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - Dechra Pharmaceuticals plc" and references "Rule 8.3 of the Takeover Code (the “Code”)". Form 8.3 is a mandatory disclosure required under the UK Takeover Code when a person holding interests in relevant securities representing 1% or more of a company involved in a takeover bid makes a dealing or holds a position. This type of filing relates directly to insider transactions or significant ownership changes during a takeover scenario. While it involves director/insider activity (like DIRS), its specific context under the Takeover Code makes it distinct. It is not a general Director's Dealing report (DIRS), nor is it a general Major Shareholding Notification (MRQ), as it is tied to a specific M&A event governed by the Takeover Code. Since there is no specific code for 'Takeover Code Disclosure Form 8.3', and it details dealings by a person with interests in securities related to an offer, it most closely aligns with M&A Activity (TAR) or, given its nature as a regulatory disclosure about ownership/dealing during a corporate action, it could be considered a specialized Regulatory Filing (RNS). However, because the core subject is the disclosure of interests/dealings related to a takeover/offer (Dechra Pharmaceuticals plc), TAR is a strong candidate. Given the options, and recognizing that this is a specific regulatory disclosure about interests during an offer, it is a specialized filing. Since the document details dealings and positions related to an offer, and TAR covers M&A Activity, I will classify it as TAR, as it is directly linked to the takeover process governed by the Code.
2023-10-04 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' concerning an offer involving 'Dechra Pharmaceuticals plc'. This type of disclosure relates to insider/significant shareholder activity during a takeover or offer period, which falls under the scope of regulatory filings related to corporate actions and ownership changes. While it involves director/insider activity (similar to DIRS), Form 8.3 is specifically mandated by the UK Takeover Code and deals with interests in securities during an offer. Since there is no specific code for Takeover Code Disclosures (like Form 8.3), and it details personal share transactions/interests by a major holder during a specific corporate event (an offer), it is best classified as a specialized regulatory filing. Given the options, 'Director's Dealing' (DIRS) is the closest thematic fit for reporting personal security interests/transactions, although this is a specific Takeover Code filing. However, since the content is a mandatory disclosure about interests and dealings in securities related to an offer, and it is not a general earnings report, annual report, or dividend notice, it is a specific regulatory disclosure. In the absence of a 'Takeover Disclosure' code, and noting that it reports dealings by a major holder, DIRS is the most appropriate category among the provided choices that covers insider/significant shareholder transactions, even though the context is a takeover bid.
2023-10-03 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. Such disclosures are mandatory filings related to takeover bids or mergers, detailing a party's interest in the securities of the offeror or offeree. This specific context strongly aligns with M&A Activity (TAR), which covers merger proposals or takeover bids, as Form 8.3 is a direct regulatory requirement during such events. It is not a general Director's Dealing (DIRS) as it is tied to a specific takeover code context, nor is it a general Regulatory Filing (RNS) because it fits the specific M&A category.
2023-10-02 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 97% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used in the context of a takeover bid (indicated by the reference to 'offeror/offeree' and the Takeover Code) to disclose a person's interest or dealing in the relevant securities. This type of disclosure, which relates to insider/significant shareholder activity during a takeover scenario, does not fit neatly into the standard SEC filings (10-K, IR, ER) or general corporate actions (DIV, SHA). It is a specific regulatory disclosure related to market activity during a corporate event. Since there is no specific code for Takeover Code Disclosures (Form 8.3), the most appropriate fallback category is "Regulatory Filings" (RNS), as it is a mandatory filing with a regulatory body (The Takeover Panel) concerning market activity.
2023-09-29 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose interests and dealings in securities during a takeover offer. This specific type of disclosure, related to insider/significant shareholder activity during a takeover context, is not explicitly covered by the provided definitions (AGM-R, 10-K, ER, etc.). However, it is a mandatory regulatory filing related to insider/significant ownership changes, often associated with M&A activity (TAR) or general insider trading disclosures (DIRS). Since it specifically deals with a person's position (interests and short positions) in securities relevant to an offer, and the closest fit among the options that deals with insider/significant ownership changes is 'Director's Dealing' (DIRS), I must evaluate if DIRS is appropriate. DIRS is defined as 'Report of personal share transactions by company directors and executives (insider trades)'. While this disclosure is by Millennium International Management LP (an investment manager) and not strictly a director, it is a mandatory disclosure of significant position changes during a potential takeover, which falls under the broader umbrella of insider/significant transaction reporting. Given the options, and recognizing that this is a specific regulatory disclosure about ownership/dealing during a takeover, it is most closely related to insider/significant transaction reporting. If a more specific 'Takeover Disclosure' code existed, it would be used. In the absence of that, DIRS is the closest category for mandatory personal/significant entity dealings disclosure. Alternatively, it could be RNS (Regulatory Filings) as a fallback, but DIRS captures the nature of the content better than a generic RNS.
2023-09-28 English
Form 8.3 - Dechra Pharmaceuticals PLC
M&A Activity Classification · 95% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals PLC' and references 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is a 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE'. This type of disclosure relates to insider/significant shareholder activity during a takeover or merger situation. Among the provided categories, 'M&A Activity' (TAR) is the closest fit as it covers merger proposals or takeover bids, and Form 8.3 is a mandatory filing during such events. It is not a general Director's Dealing (DIRS) as it is specifically tied to the Takeover Code rules during an offer period.
2023-09-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.